Cargando…
The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy
BACKGROUND: To investigate a prognostic role of gross tumor volume (GTV) changes on survival outcomes following concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) patients. METHODS: We enrolled 191 patients with stage III NSCLC from 2001 to 2009 undergoing definitive...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268851/ https://www.ncbi.nlm.nih.gov/pubmed/25498887 http://dx.doi.org/10.1186/s13014-014-0283-6 |
_version_ | 1782349301981118464 |
---|---|
author | Koo, Tae Ryool Moon, Sung Ho Lim, Yu Jin Kim, Ja Young Kim, Yeonjoo Kim, Tae Hyun Cho, Kwan Ho Han, Ji-Youn Lee, Young Joo Yun, Tak Kim, Heung Tae Lee, Jin Soo |
author_facet | Koo, Tae Ryool Moon, Sung Ho Lim, Yu Jin Kim, Ja Young Kim, Yeonjoo Kim, Tae Hyun Cho, Kwan Ho Han, Ji-Youn Lee, Young Joo Yun, Tak Kim, Heung Tae Lee, Jin Soo |
author_sort | Koo, Tae Ryool |
collection | PubMed |
description | BACKGROUND: To investigate a prognostic role of gross tumor volume (GTV) changes on survival outcomes following concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) patients. METHODS: We enrolled 191 patients with stage III NSCLC from 2001 to 2009 undergoing definitive CCRT. The GTV of 157 patients was delineated at the planning CT prior to CCRT and with a follow-up CT 1 month after CCRT. We assessed the volumetric parameters of pre-treatment GTV (GTV(pre)) post-treatment GTV (GTV(post)), and volume reduction ratio of GTV (VRR). The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) and locoregional progression-free survival (LRPFS). The best cut-off value was defined as that which exhibited the maximum difference between the two groups. RESULTS: The median follow-up duration was 52.7 months in surviving patients. Median survival, 3-year OS, PFS and LRPFS rates were 25.5 months, 36.4%, 23.0%, and 45.0%, respectively. The selected cut-off values were 50 cm(3) for GTV(pre), 20 cm(3) for GTV(post), and 50% for VRR. The smaller GTV(pre) and GTV(post) values were associated with better OS (p < 0.001 and p = 0.015) and PFS (p = 0.001 and p = 0.004), respectively, upon univariate analysis. The higher VRR of > 50% was associated with a trend toward poorer OS (p = 0.004) and PFS (p = 0.054). Upon multivariate analysis, smaller GTV(pre) indicated significantly improved OS (p = 0.001), PFS (p = 0.013) and LRPFS (p = 0.002), while smaller GTV(post) was marginally significant for PFS (p = 0.086). Higher VRR was associated with a trend toward poorer OS (p = 0.075). CONCLUSIONS: In patients with stage III NSCLC undergoing definitive CCRT, GTV(pre) was an independent prognostic factor of survival. Notably, improved outcome was not correlated with higher VRR after short-term follow-up with CT alone. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-014-0283-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4268851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42688512014-12-17 The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy Koo, Tae Ryool Moon, Sung Ho Lim, Yu Jin Kim, Ja Young Kim, Yeonjoo Kim, Tae Hyun Cho, Kwan Ho Han, Ji-Youn Lee, Young Joo Yun, Tak Kim, Heung Tae Lee, Jin Soo Radiat Oncol Research BACKGROUND: To investigate a prognostic role of gross tumor volume (GTV) changes on survival outcomes following concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) patients. METHODS: We enrolled 191 patients with stage III NSCLC from 2001 to 2009 undergoing definitive CCRT. The GTV of 157 patients was delineated at the planning CT prior to CCRT and with a follow-up CT 1 month after CCRT. We assessed the volumetric parameters of pre-treatment GTV (GTV(pre)) post-treatment GTV (GTV(post)), and volume reduction ratio of GTV (VRR). The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) and locoregional progression-free survival (LRPFS). The best cut-off value was defined as that which exhibited the maximum difference between the two groups. RESULTS: The median follow-up duration was 52.7 months in surviving patients. Median survival, 3-year OS, PFS and LRPFS rates were 25.5 months, 36.4%, 23.0%, and 45.0%, respectively. The selected cut-off values were 50 cm(3) for GTV(pre), 20 cm(3) for GTV(post), and 50% for VRR. The smaller GTV(pre) and GTV(post) values were associated with better OS (p < 0.001 and p = 0.015) and PFS (p = 0.001 and p = 0.004), respectively, upon univariate analysis. The higher VRR of > 50% was associated with a trend toward poorer OS (p = 0.004) and PFS (p = 0.054). Upon multivariate analysis, smaller GTV(pre) indicated significantly improved OS (p = 0.001), PFS (p = 0.013) and LRPFS (p = 0.002), while smaller GTV(post) was marginally significant for PFS (p = 0.086). Higher VRR was associated with a trend toward poorer OS (p = 0.075). CONCLUSIONS: In patients with stage III NSCLC undergoing definitive CCRT, GTV(pre) was an independent prognostic factor of survival. Notably, improved outcome was not correlated with higher VRR after short-term follow-up with CT alone. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-014-0283-6) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-13 /pmc/articles/PMC4268851/ /pubmed/25498887 http://dx.doi.org/10.1186/s13014-014-0283-6 Text en © Koo et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Koo, Tae Ryool Moon, Sung Ho Lim, Yu Jin Kim, Ja Young Kim, Yeonjoo Kim, Tae Hyun Cho, Kwan Ho Han, Ji-Youn Lee, Young Joo Yun, Tak Kim, Heung Tae Lee, Jin Soo The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
title | The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
title_full | The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
title_fullStr | The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
title_full_unstemmed | The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
title_short | The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
title_sort | effect of tumor volume and its change on survival in stage iii non-small cell lung cancer treated with definitive concurrent chemoradiotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268851/ https://www.ncbi.nlm.nih.gov/pubmed/25498887 http://dx.doi.org/10.1186/s13014-014-0283-6 |
work_keys_str_mv | AT kootaeryool theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT moonsungho theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT limyujin theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimjayoung theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimyeonjoo theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimtaehyun theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT chokwanho theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT hanjiyoun theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT leeyoungjoo theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT yuntak theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimheungtae theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT leejinsoo theeffectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kootaeryool effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT moonsungho effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT limyujin effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimjayoung effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimyeonjoo effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimtaehyun effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT chokwanho effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT hanjiyoun effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT leeyoungjoo effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT yuntak effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT kimheungtae effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy AT leejinsoo effectoftumorvolumeanditschangeonsurvivalinstageiiinonsmallcelllungcancertreatedwithdefinitiveconcurrentchemoradiotherapy |